Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote & News

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 977 5700

Website: apellis.com

Address:

100 Fifth Avenue, Waltham, United States

Whiskeyunderthebed Oct. 2 at 2:04 PM

$APLS with what ...Legos

1 · Reply

SweepCastApp Oct. 2 at 6:27 AM

$APLS: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $35 Exp on 01/15/2027 with Premium of $135K and showing BULLISH Sentiment

0 · Reply

monoksop Oct. 2 at 3:54 AM

$APLS Building

0 · Reply

Whiskeyunderthebed Sep. 30 at 7:48 PM

$APLS the bio market is screaming and nobody wants to touch this POS

1 · Reply

twin_dad Sep. 30 at 5:38 PM

$APLS on the way back

0 · Reply

scott52 Sep. 30 at 3:27 PM

$APLS I filed an SEC complaint against Salveen Richter. I don't expect anything to come of it. But I've been doing this a long time and the stock action in September was hinky as fuck.

0 · Reply

highnihilism Sep. 30 at 8:34 AM

$PBI Pitney Bowes: 269 trades, $174K vs $349K avg (0.50x). $149K calls / $25K puts. $APLS Apellis Pharma: 33 trades, $174K vs $323K avg (0.54x). $148K calls / $26K puts. $VIRT Virtu Financial: 195 trades, $176K vs $82K avg (2.15x !). $148K calls / $28K puts. $MUB iShares National Muni Bond ETF: 36 trades, $160K vs $288K avg (0.56x). $148K calls / $12K puts.

0 · Reply

Whiskeyunderthebed Sep. 29 at 7:28 PM

$APLS

0 · Reply

scott52 Sep. 29 at 2:39 PM

$APLS You'd think the SEC would investigate this. Stock down every day for two weeks just before Salveen drops a nasty sell rec. And no one got wind of this? The sell off had nothing to do with her? In what world? It's a joke.

1 · Reply

scott52 Sep. 26 at 7:16 PM

$APLS I think maybe that's Salveen's shot across the bow to Cedric: do a deal with us NOW or we'll bury you. If so, I approve of such tactics. Anything to drag Cedric's ass to the negotiating table is fair play as far as I'm concerned. Back in 2023, peak sales estimates were $3B. Salveen is now ONE THIRD that amount. This is a disaster. But what's worse is Cedric has no answers. Pay copays forever? Give it away for free forever? Even the Fonz can't save this sinking ship.

1 · Reply

Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

Sep 9, 2025, 12:55 PM EDT - 25 days ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)

Sep 4, 2025, 11:20 AM EDT - 4 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 3, 2025, 11:24 AM EDT - 4 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 7:00 AM EDT - 5 weeks ago

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 14, 2025, 12:12 PM EDT - 7 weeks ago

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Aug 2, 2025, 4:23 AM EDT - 2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 2:29 PM EDT - 2 months ago

Apellis Pharmaceuticals: The Picture Becomes Clearer

Jul 31, 2025, 7:05 AM EDT - 2 months ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 12:12 PM EDT - 2 months ago

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

Jul 28, 2025, 7:19 PM EDT - 2 months ago

FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Jul 24, 2025, 7:00 AM EDT - 2 months ago

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 2 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Jul 1, 2025, 7:35 AM EDT - 3 months ago

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Jul 1, 2025, 7:00 AM EDT - 3 months ago

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Jun 6, 2025, 9:15 AM EDT - 4 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Jun 4, 2025, 7:00 AM EDT - 4 months ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:28 AM EDT - 4 months ago

Apellis Pharmaceuticals: Have Some Patience

May 7, 2025, 1:18 PM EDT - 5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 5 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 5 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 30, 2025, 7:00 AM EDT - 5 months ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 5 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 1, 2025, 2:11 PM EDT - 6 months ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 7:00 AM EDT - 6 months ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Mar 5, 2025, 2:06 PM EST - 7 months ago

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:04 PM EST - 7 months ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 2, 2025, 2:08 AM EST - 7 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:05 AM EST - 7 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 7 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 2:00 AM EST - 8 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Feb 14, 2025, 7:00 AM EST - 8 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 4, 2025, 4:05 PM EST - 8 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 27, 2025, 4:00 PM EST - 8 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Jan 21, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect

Jan 20, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out

Jan 19, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 9 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 16, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation

Jan 15, 2025, 10:00 AM EST - 9 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 14, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Jan 13, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Jan 13, 2025, 9:00 AM EST - 9 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect

Jan 9, 2025, 10:00 AM EST - 9 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation

Jan 6, 2025, 12:30 PM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out

Jan 6, 2025, 7:00 AM EST - 9 months ago

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Whiskeyunderthebed Oct. 2 at 2:04 PM

$APLS with what ...Legos

1 · Reply

SweepCastApp Oct. 2 at 6:27 AM

$APLS: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $35 Exp on 01/15/2027 with Premium of $135K and showing BULLISH Sentiment

0 · Reply

monoksop Oct. 2 at 3:54 AM

$APLS Building

0 · Reply

Whiskeyunderthebed Sep. 30 at 7:48 PM

$APLS the bio market is screaming and nobody wants to touch this POS

1 · Reply

twin_dad Sep. 30 at 5:38 PM

$APLS on the way back

0 · Reply

scott52 Sep. 30 at 3:27 PM

$APLS I filed an SEC complaint against Salveen Richter. I don't expect anything to come of it. But I've been doing this a long time and the stock action in September was hinky as fuck.

0 · Reply

highnihilism Sep. 30 at 8:34 AM

0 · Reply

Whiskeyunderthebed Sep. 29 at 7:28 PM

$APLS

0 · Reply

scott52 Sep. 29 at 2:39 PM

1 · Reply

scott52 Sep. 26 at 7:16 PM

1 · Reply

Whiskeyunderthebed Sep. 26 at 5:21 PM

$APLS maybe the chemistry was not there with Cedric and Salveen Richter...

0 · Reply

ChangeisNewConstant Sep. 26 at 5:00 PM

$APLS I am hoping happy and good days are ahead of us as Goldman also can’t push down more

0 · Reply

JarvisFlow Sep. 26 at 4:51 PM

Goldman Sachs has adjusted their stance on Apellis Pharmaceuticals ( $APLS ), setting the rating to Sell with a target price of 26 → 18.

0 · Reply

buylowandwait Sep. 26 at 2:46 PM

$APLS Goldman Sucks downgrade this tick. I am more optimistic now that I know who is behind the push downward... Fundamental prevails, hopefully GA resumes growth and C3G/IC-MPGN does wonders to patients.

0 · Reply

Ohzipit Sep. 26 at 2:43 PM

$APLS if a Goldman sell rating cant bring the stock down hopefully the worst is over.

2 · Reply

scott52 Sep. 26 at 1:42 PM

$APLS Well, I can't say I'm surprised by this. Cedric has tried to put a happy face on the Syfovre trajectory during the fireside chats, but the bottom line is that they inflated the TAM and growth has ceased. Not to mention paying $13M for copays and giving away samples every quarter. I give up on bios. They are all cancerous.

0 · Reply

Rabinovich Sep. 26 at 1:19 PM

$APLS Well now we know who was shorting it. The usual suspects - assholes.

2 · Reply

Jennifur Sep. 26 at 12:03 PM

$APLS if i had hundreds of millions? this would be the first stock in my life that I would ever short and short it to bankruptcy with a smile on my face

0 · Reply

Pharmer23 Sep. 26 at 11:54 AM

$APLS the only good thing I’ve done with this stock is unload my bags on the last pop . Looking to rebuy in the teens . It has been a painful ride . Hopefully kidney sales can turn this around eventually .

1 · Reply

Jennifur Sep. 26 at 11:29 AM

$APLS SELL!!!! $14.77 is coming. maybe even a trip to $10. serves them right. That’s a whopper of a downgrade with the first major to go with a SELL in a LONG time! GS has obviously seen enough of the BS Investing.com - Goldman Sachs downgraded Apellis Pharmaceuticals (NASDAQ:APLS) from Neutral to Sell and lowered its price target to $18.00, citing concerns about the growth trajectory of the company’s geographic atrophy treatment Syfovre. The stock, currently trading at $22.22, has already declined over 30% year-to-date

1 · Reply

Jennifur Sep. 26 at 11:25 AM

$APLS cedric and the rest should be investigated for fraud no doubt

0 · Reply

notreload_ai Sep. 26 at 11:24 AM

Goldman Sachs cut $APLS stock to "Sell," lowering the price target to $18. Risks include slow near-term growth and lower Syfovre sales. https://notreload.xyz/goldman-sachs-downgrades-apellis-sell/

0 · Reply

Market Cap	2.92B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-25.32%
Debt to Equity Ratio	2.31

Volume	3,510,800
Avg Vol	2,539,314
Day's Range	N/A - N/A
Shares Out	126.29M
Stochastic %K	95%
Beta	0.69
Analysts	Sell
Price Target	$36.95